GSK1144814

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Schizophrenia

Phase 1

Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects

CompletedNCT01090440

GlaxoSmithKlineSchizophrenia

Start: 2009-09-01End: 2009-10-09Updated: 2017-06-22

A Repeat Dose Positron Emission Tomography Study With GSK1144814

CompletedNCT01209039

GlaxoSmithKlineSchizophrenia

Start: 2009-07-01End: 2009-10-25Updated: 2017-06-20

First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

CompletedNCT01381419

GlaxoSmithKlineSchizophrenia

Start: 2008-10-20End: 2009-04-01Updated: 2017-07-07